Literature DB >> 16973562

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Manish Sagar1, Xueling Wu, Sandra Lee, Julie Overbaugh.   

Abstract

Over the course of infection, human immunodeficiency virus type 1 (HIV-1) continuously adapts to evade the evolving host neutralizing antibody responses. Changes in the envelope variable loop sequences, particularly the extent of glycosylation, have been implicated in antibody escape. To document modifications that potentially influence antibody susceptibility, we compared envelope variable loops 1 and 2 (V1-V2) from multiple sequences isolated at the primary phase of infection to those isolated around 2 to 3 years into the chronic phase of infection in nine women with HIV-1 subtype A. HIV-1 sequences isolated during chronic infection had significantly longer V1-V2 loops, with a significantly higher number of potential N-linked glycosylation sites, than the sequences isolated early in infection. To assess the effects of these V1-V2 changes on antibody neutralization and infectivity, we created chimeric envelope sequences, which incorporated a subject's V1-V2 sequences into a common subtype A envelope backbone and then used them to generate pseudotyped viruses. Compared to the parent virus, the introduction of a subject's early-infection V1-V2 envelope variable loops rendered the chimeric envelope more sensitive to that subject's plasma samples but only to plasma samples collected >6 months after the sequences were isolated. Neutralization was not detected with the same plasma when the early-infection V1-V2 sequences were replaced with chronic-infection V1-V2 sequences, suggesting that changes in V1-V2 contribute to antibody escape. Pseudotyped viruses with V1-V2 segments from different times in infection, however, showed no significant difference in neutralization sensitivity to heterologous pooled plasma, suggesting that viruses with V1-V2 loops from early in infection were not inherently more neutralization sensitive. Pseudotyped viruses bearing chimeric envelopes with early-infection V1-V2 sequences showed a trend in infecting cells with low CD4 concentrations more efficiently, while engineered viruses with V1-V2 sequences isolated during chronic infection were moderately better at infecting cells with low CCR5 concentrations. These studies suggest that changes within the V1-V2 envelope domains over the course of an infection influence sensitivity to autologous neutralizing antibodies and may also impact host receptor/coreceptor interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973562      PMCID: PMC1617272          DOI: 10.1128/JVI.00141-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression.

Authors:  T Shioda; S Oka; X Xin; H Liu; R Harukuni; A Kurotani; M Fukushima; M K Hasan; T Shiino; Y Takebe; A Iwamoto; Y Nagai
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.

Authors:  J Cao; N Sullivan; E Desjardin; C Parolin; J Robinson; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 4.  The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins.

Authors:  R D Marshall
Journal:  Biochem Soc Symp       Date:  1974

5.  Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.

Authors:  S R Bartz; M A Vodicka
Journal:  Methods       Date:  1997-08       Impact factor: 3.608

6.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Capsid is a dominant determinant of retrovirus infectivity in nondividing cells.

Authors:  Masahiro Yamashita; Michael Emerman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages.

Authors:  S R Lewin; S Sonza; L B Irving; C F McDonald; J Mills; S M Crowe
Journal:  AIDS Res Hum Retroviruses       Date:  1996-07-01       Impact factor: 2.205

9.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.

Authors:  S Modrow; B H Hahn; G M Shaw; R C Gallo; F Wong-Staal; H Wolf
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.

Authors:  L Wu; W A Paxton; N Kassam; N Ruffing; J B Rottman; N Sullivan; H Choe; J Sodroski; W Newman; R A Koup; C R Mackay
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  173 in total

1.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

3.  Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.

Authors:  Evelien M Bunnik; Zelda Euler; Matthijs R A Welkers; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  Nat Med       Date:  2010-08-29       Impact factor: 53.440

4.  Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.

Authors:  Diana Edo-Matas; Philippe Lemey; Jennifer A Tom; Cèlia Serna-Bolea; Agnes E van den Blink; Angélique B van 't Wout; Hanneke Schuitemaker; Marc A Suchard
Journal:  Mol Biol Evol       Date:  2010-12-06       Impact factor: 16.240

5.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

6.  HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors:  Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

7.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

8.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

9.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

10.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.